Merck and Lundbeck: Sanofi set to benefit from drug failure

May 2007
PharmaWatch: CNS;May2007, Vol. 6 Issue 5, p9
Market Research Report
The article reports on the impact of the negative result of the phase III data for gaboxadol manufactured by Merck & Co. Inc. and Lundbeck on the market leader Sanofi-Aventis. Sanofi's drug Ambien will not face considerable competition from a Merck marketed alternative. The market for Sanofi’s own Phase III pipeline insomnia drug eplivanserin will be clearer.


Related Articles

  • Sleep Disorders Update.  // PharmaWatch: CNS;Aug2006, Vol. 5 Issue 8, p13 

    The article provides update in sleep disorders in the U.S. The investigational drug Gaboxadol being developed by Merck & Co. Inc. and H LundbeckA/S company has show to improve deep sleep and key sleep measures in phase II trial in adult patients with both primary and transient insomnia. A study...

  • Merck and Lundbeck: Sanofi set to benefit from drug failure.  // PharmaWatch: Monthly Review;May2007, Vol. 6 Issue 5, p15 

    The article reports that the drug gaboxadol has not been found to be effective in the treatment of insomnia. It causes side effects such as hallucinations, dizziness and vomiting when administered at only twice the recommended dose. This was revealed by Phase III trials of the drug which is...

  • Cardiovascular News Round-up.  // PharmaWatch: Monthly Review;Oct2007, Vol. 6 Issue 10, p10 

    The article offers news briefs related to the pharmaceutical industry. Merck & Co. Inc. has completed the acquisition of NovaCardia Inc., a privately held clinical-stage pharmaceutical company focused on cardiovascular disease. Meanwhile, Sanofi Aventis SA has announced that one-year findings...

  • CNS News Round-Up.  // PharmaWatch: CNS;May2007, Vol. 6 Issue 5, p2 

    The article reports developments in the pharmaceutical industry. Eli Lilly's drug Permax was removed by Food and Drug Administration from the market after reports published about the negative side effects of the treatment. The development of the gaboxadol drug from Merck & Co. and Lundbeck has...

  • Merck to license sleep disorder drug from Lundbeck.  // PharmaWatch: CNS;March 2004, Vol. 3 Issue 3, p19 

    Reports on the license agreement between Merck & Co. Inc. and H. Lundbeck AS. Aim of the agreement to license a sleep disorder treatment in the late stages of development; Financial terms of the agreement; Terms of the agreement.

  • Merck adds phase III sleep disorder drug to pipeline.  // Chemical Market Reporter;2/16/2004, Vol. 265 Issue 7, p3 

    Reports on Merck & Co. Inc.'s pact with H. Lundbeck AS for the development and commercialization of the sleep disorder drug gaboxadol.

  • Increased haemorrhage risk with idraparinux leads to trial termination.  // Reactions Weekly;2/2/2008, Issue 1187, p1 

    The article reports on the termination of the Amadeus trial, a randomized, open-label non-inferiority trial funded by Sanofi-Aventis which examined the drug idraparinux. The study was discontinued due to clinically relevant episodes of haemorrhage in the idraparinux sodium group after 4576...

  • Other CNS News Headlines January 15, 2004 - February 14, 2004.  // PharmaWatch: CNS;March 2004, Vol. 3 Issue 3, p17 

    Reports business developments in the pharmaceutical industry as of March 2004. Lawsuit filed by Shire against Nostrum over epilepsy drug; Approval for GlaxoSmithKline PLC's Lamictal drug; License agreement between Merck & Co. Inc. and Lundbeck Ltd.

  • CLINIC ROUNDUP.  // BioWorld Today;3/29/2007, Vol. 18 Issue 61, p3 

    The article offers news briefs related to the pharmaceutical industry. Merck & Co. Inc. of New Jersey and H. Lundbeck AS of Copenhagen, Denmark terminated the late-stage trials of gaboxadol, a medicine for insomnia. NicOx SA of Sophia Anapolis, France in cooperation with Pfizer Inc. of New York...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics